Share this article:

Abstract

Extrapolations from pharmacological research have led some authors to suggest restrictions or contraindications for the use of Echinacea. This article examines the known chemistry and pharmacology of the various Echinacea species and products, and challenges some of these popular concepts. In particular, the hypotheses that Echinacea is a T cell activator and that it will accelerate pathology in HIV/AIDS, are found to be unsupported by careful analysis of known data. These misunderstandings have arisen mainly from enthusiastic extrapolations of in vitro data on polysaccharide components. The low levels of polysaccharides in most Echinacea products, particularly traditional extracts and tinctures, and their poor bioavailability suggest in most cases the therapeutic activity of Echinacea is due to other component fractions, including the alkylamides. The suggestion that Echinacea should not be prescribed for extended periods of time will be examined in a second article. (Alt Med Rev 1997;2(2):87-93)

Share this article: